肝硬化患者血清瘦素水平的测定及其与高胰岛素血症的关系

瘦素(leptin)是近年来新发现的一种激素,主要作用是调节机体的摄食和能量代谢[1]。肝硬化患者常存在各种代谢紊乱、营养不良、高胰岛素血症及胰岛素抵抗。因此,瘦素在肝硬化中的作用日益受到关注[2]。本研究旨在通过研究肝硬化患者血清瘦素的水平及其与胰岛素之间的相关性,明确     

p53,p16,PCNA蛋白在食管癌中的表达及其临床意义

目的探讨p53,p16,PCNA蛋白在食管癌中的表达及临床意义。方法用免疫组织化学染色SP法对62例食管癌标本进行p53,p16,PCNA蛋白测定。结果62例食管癌中,p53,PCNA蛋白阳性表达均为71.0%(44/62),p16缺失率48.4%(30/62)。p16缺失与肿瘤浸润深度、淋巴结转移密切相关(P<0.05、P<0.01)。而p53,PCNA蛋白同时表达56.5%(35/62),亦与肿瘤浸润深度、淋巴结转移密切相关(P<0.05、P<0.01)。结论食管癌p53,PCNA蛋白同时表达及p16缺失可视为危险预后因素。     

ALPPS治疗巨大原发性肝癌患者近远期疗效研究

目的 探讨联合肝脏分隔和门静脉结扎的二步肝切除术(ALPPS)治疗巨大原发性肝癌(PLC)患者的近远期疗效.方法 2016年1月～2018年2月我院诊治的98例巨大PLC患者,其中20例接受ALPPS治疗(A组),38例在经肝动脉化疗栓塞术(TACE)治疗后手术切除肿瘤(B组),和40例接受直接手术切除肿瘤(C组).术...     

Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States

ObjectiveTo understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists).MethodsCross-sectional surveys of OAB patients and OAB-treating physicians in the USA were conducted. Patients receiving monotherapy with antimuscarinics were categorized by OAB treatment history: monotherapy only; third-line procedures (e.g., onabotulinumtoxinA injections) and combination therapy; third-line therapy only; and combination therapy only. The patient survey assessed therapy choice drivers and barriers, treatment satisfaction and sociodemographic/clinical characteristics. The physician survey assessed drivers of and barriers to OAB treatment choices.ResultsOf 200 patients, 86.5% reported involvement in treatment decision-making; doctor’s recommendation was the most frequently considered factor (84.4%). Most patients (71%) were unaware of combination therapy. The primary reason why those patients aware of combination therapy had not used it (N = 43/200; 21%) was physician recommendation of other treatments (69.8%). For physicians (N = 50), the most frequently considered factors when prescribing OAB treatment were effectiveness (92.0%) and side effects (84.0%); 70% prescribed combination therapy, primarily for symptom severity (82.9%). The main reasons for not prescribing combination therapy were cost/insurance coverage (80%) and lack of information (53.3%).ConclusionsShared decision-making guided treatment decisions; the main considerations were treatment safety and efficacy.     

论肺心病的临床疗效评价方法

从现代临床报道着手,分析了肺心病的临床疗效评价方法运用现状,认为目前本病的疗效评价方法可归为3类,即以症状体征为主的综合评价法,以实验指标为主的评价法,以生存质量和结局性指标为主的评价法。然后对这些评价方法的临床价值、应用范围、优势与不足等进行了分析与点评。最后提出对肺心病的临床疗效评价中应该突出中医特色,应根据研究类型、治疗方法、疾病阶段、评价期限等进行认真分析和恰当选择,强调了科学选择评价方法、客观反应中医药疗效的重要性。     

心血瘀阻证大鼠血浆代谢网络模型分析

目的：探讨心血瘀阻证大鼠血浆代谢网络模型。方法：代谢通路分析采用KEGG 数据库,代谢产物分子注释、相关的酶或转运蛋白及其相关性质分析采用HMDB 数据库,代谢网络模型可视化采用metPA 网络软件。结果：9 个代谢产物参与了15 条代谢通路,其中泛酸盐和CoA 生物合成、丙酸代谢、不饱和脂肪酸生物合成通路影响值P＜0.05。结论：泛酸盐和CoA 生物合成、丙酸代谢、不饱和脂肪酸生物合成通路参与大鼠心血瘀阻证的病理过程。     

上海市1152名教育和卫生工作者亚健康状态中医证候分布特征

目的探讨亚健康状态的中医基本证候分布特征。方法基于临床流行病学方法,2009年10-12月对上海市静安区教育和卫生工作者进行横断面调查,总结亚健康的主要中医症状、体征及基本证型分布情况。结果 1502名调查对象中有1152名处于亚健康状态;其临床症状以疲劳、疲乏休息后不能缓解、头昏沉、眼睛干涩、眼睛酸胀、咽干、记事困难、食欲减退、饮水减少、易汗出、疼痛、消极感、易怒、入睡困难、早醒、睡眠质量差、精力不充沛、精力下降、易感冒、怕冷等较为常见;体征以精神不振、精神疲惫、面色萎黄、语音低怯、舌体胖、舌淡白、苔腻、脉细等较为常见;常见证型为肝郁脾虚（20.31%）、心脾两虚（16.49%）、脾虚湿阻（14.76%）、肝气郁结（11.98%）、肝肾阴虚（11.63%）、痰热内扰（8.07%）、肺脾气虚（7.99%）、肝郁化火（3.13%）。结论基于横断面调查,可初步确定上海市静安区教育和卫生工作者亚健康的中医症状、体征及基本证型分布,为中医药干预提供依据。     

栀子卷叶螟的发生规律及防治研究

目的:通过对栀子卷叶螟Archernius tropicalis的发生规律及防治研究,为防治提供依据。方法:定点观察和药效试验。结果:该虫在湖北省孝感地区一年发生四代。世代重叠,以幼虫在枯叶中结薄茧越冬,翌年3月恢复取食,4月上旬开始化蛹,4月中、下旬羽化产卵,至6月中旬第一代幼虫发生为害,7月上、中旬至8月中旬为第二代幼虫盛发期,第三代幼虫则于9月上、中旬出现危害至11月上、中旬,第四代幼虫于11月下旬陆续结薄茧进入越冬休眠。选用市售5种药剂试验的结果,只要使用有效浓度在防治适期施药,均能获得90%以上的防治效果。结论:结合栀子卷叶螟的发生规律在其各代幼虫为害期喷施本试验选用的市售5种药剂均能有效防治栀子卷叶螟。     

脑缺血后抑郁大鼠皮层及海马IP3表达及中药的干预作用

目的：从磷脂酰肌醇（PI）信号传导通路上重要调节因子IP3的角度,探讨脑缺血后抑郁模型磷脂酰肌醇（PI）信号传导通路的变化及中药颐脑解郁方的干预作用。方法：在脑缺血后抑郁模型上,采用AlphaScreen受体竞争机制,观察脑缺血后抑郁大鼠前额叶皮层、海马IP3含量的变化及中药颐脑解郁方的干预作用。结果：脑缺血后抑郁模型大鼠皮层及海马IP3含量明显高于正常组,模型组IP3的含量明显高于治疗组。结论：脑缺血后抑郁模型大鼠脑皮层及海马IR含量增加,中药颐脑解郁方能使之明显下调,提示脑缺血后抑郁IPl含量增加,颐脑解郁方的抗抑郁作用可能与调节受体后PI信号通路有关。     

Selective Antibacterial Activity of Patchouli Alcohol Against Helicobacter pylori Based on Inhibition of Urease

The aim of this study is to evaluate the antibacterial activity and urease inhibitory effects of patchouli alcohol (PA), the bioactive ingredient isolated from Pogostemonis Herba, which has been widely used for the treatment of gastrointestinal disorders. The activities of PA against selected bacteria and fungi were determined by agar dilution method. It was demonstrated that PA exhibited selective antibacterial activity against Helicobacter pylori, without influencing the major normal gastrointestinal bacteria. Noticeably, the antibacterial activity of PA was superior to that of amoxicillin, with minimal inhibition concentration value of 78 µg/mL. On the other hand, PA inhibited ureases from H. pylori and jack bean in concentration‐dependent fashion with IC₅₀ values of 2.67 ± 0.79 mM and 2.99 ± 0.41 mM, respectively. Lineweaver‐Burk plots indicated that the type of inhibition was non‐competitive against H. pylori urease whereas uncompetitive against jack bean urease. Reactivation of PA‐inactivated urease assay showed DL‐dithiothreitol, the thiol reagent, synergistically inactivated urease with PA instead of enzymatic activity recovery. In conclusion, the selective H. pylori antibacterial activity along with urease inhibitory potential of PA could make it a possible drug candidate for the treatment of H. pylori infection. Copyright © 2014 John Wiley & Sons, Ltd.